For research use only. Not for therapeutic Use.
MPT0B392 (Cat No.:I018778) is a novel small-molecule compound with potential anticancer activity. It acts as a multi-kinase inhibitor, targeting several signaling pathways involved in cancer progression and metastasis. MPT0B392 has been shown to inhibit key kinases such as VEGFR2, FGFR1, PDGFRβ, and c-Kit, which are involved in angiogenesis, tumor growth, and metastasis. By inhibiting these kinases, MPT0B392 interferes with signaling pathways that promote tumor cell proliferation, survival, and angiogenesis. Preclinical studies have demonstrated its efficacy in suppressing tumor growth and reducing metastasis in various cancer models. MPT0B392 holds promise as a potential therapeutic agent for the treatment of cancer, and further research and clinical studies are ongoing to evaluate its efficacy and safety in cancer patients.
| Catalog Number | I018778 |
| CAS Number | 1346169-92-3 |
| Molecular Formula | C₁₉H₂₀N₂O₆S |
| Purity | ≥95% |
| IUPAC Name | 6-methoxy-2-(3,4,5-trimethoxyphenyl)sulfonylquinolin-5-amine |
| InChI | InChI=1S/C19H20N2O6S/c1-24-14-7-6-13-12(18(14)20)5-8-17(21-13)28(22,23)11-9-15(25-2)19(27-4)16(10-11)26-3/h5-10H,20H2,1-4H3 |
| InChIKey | RBBRZMLZQCYQJM-UHFFFAOYSA-N |
| SMILES | COC1=C(C2=C(C=C1)N=C(C=C2)S(=O)(=O)C3=CC(=C(C(=C3)OC)OC)OC)N |
| Reference | [1]. Chao MW, et al. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells. Oncotarget. 2017 Apr,8(17):27772-27785. |
